Cellular and molecular immunology of lung cancer

Therapeutic implications

Austin Huy Nguyen, Ilya Berim, Devendra K. Agrawal

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Although the incidence of lung cancer is declining, the prognosis remains poor. This is likely due to lack of early detection and only recent developments in selective cancer therapies. Key immune cells involved in the pathogenesis of lung cancer include CD4+ T lymphocytes, macrophages, dendritic cells and NK cells. The growing understanding of these cells indicates a highly complex and intertwined network of their involvement in each stage of lung cancer. Immune cell types and numbers affect prognosis and could offer an opportunity for clinical therapeutic applications. However, an incomplete understanding of immune cell involvement and the underlying processes in lung cancer still remain. Deeper investigation focusing on the role of the immune cells will further the understanding of lung carcinogenesis and develop novel therapeutic approaches for the treatment and management of patients with more specialized and selective lung cancer.

Original languageEnglish
Pages (from-to)1711-1730
Number of pages20
JournalExpert Review of Clinical Immunology
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Allergy and Immunology
Lung Neoplasms
Therapeutics
Natural Killer Cells
Dendritic Cells
Carcinogenesis
Cell Count
Macrophages
T-Lymphocytes
Lung
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Cellular and molecular immunology of lung cancer : Therapeutic implications. / Nguyen, Austin Huy; Berim, Ilya; Agrawal, Devendra K.

In: Expert Review of Clinical Immunology, Vol. 10, No. 12, 01.12.2014, p. 1711-1730.

Research output: Contribution to journalReview article

@article{290af1770c3a458cad96efdf8bcb5a34,
title = "Cellular and molecular immunology of lung cancer: Therapeutic implications",
abstract = "Although the incidence of lung cancer is declining, the prognosis remains poor. This is likely due to lack of early detection and only recent developments in selective cancer therapies. Key immune cells involved in the pathogenesis of lung cancer include CD4+ T lymphocytes, macrophages, dendritic cells and NK cells. The growing understanding of these cells indicates a highly complex and intertwined network of their involvement in each stage of lung cancer. Immune cell types and numbers affect prognosis and could offer an opportunity for clinical therapeutic applications. However, an incomplete understanding of immune cell involvement and the underlying processes in lung cancer still remain. Deeper investigation focusing on the role of the immune cells will further the understanding of lung carcinogenesis and develop novel therapeutic approaches for the treatment and management of patients with more specialized and selective lung cancer.",
author = "Nguyen, {Austin Huy} and Ilya Berim and Agrawal, {Devendra K.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1586/1744666X.2014.975692",
language = "English",
volume = "10",
pages = "1711--1730",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Cellular and molecular immunology of lung cancer

T2 - Therapeutic implications

AU - Nguyen, Austin Huy

AU - Berim, Ilya

AU - Agrawal, Devendra K.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Although the incidence of lung cancer is declining, the prognosis remains poor. This is likely due to lack of early detection and only recent developments in selective cancer therapies. Key immune cells involved in the pathogenesis of lung cancer include CD4+ T lymphocytes, macrophages, dendritic cells and NK cells. The growing understanding of these cells indicates a highly complex and intertwined network of their involvement in each stage of lung cancer. Immune cell types and numbers affect prognosis and could offer an opportunity for clinical therapeutic applications. However, an incomplete understanding of immune cell involvement and the underlying processes in lung cancer still remain. Deeper investigation focusing on the role of the immune cells will further the understanding of lung carcinogenesis and develop novel therapeutic approaches for the treatment and management of patients with more specialized and selective lung cancer.

AB - Although the incidence of lung cancer is declining, the prognosis remains poor. This is likely due to lack of early detection and only recent developments in selective cancer therapies. Key immune cells involved in the pathogenesis of lung cancer include CD4+ T lymphocytes, macrophages, dendritic cells and NK cells. The growing understanding of these cells indicates a highly complex and intertwined network of their involvement in each stage of lung cancer. Immune cell types and numbers affect prognosis and could offer an opportunity for clinical therapeutic applications. However, an incomplete understanding of immune cell involvement and the underlying processes in lung cancer still remain. Deeper investigation focusing on the role of the immune cells will further the understanding of lung carcinogenesis and develop novel therapeutic approaches for the treatment and management of patients with more specialized and selective lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84911119625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911119625&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2014.975692

DO - 10.1586/1744666X.2014.975692

M3 - Review article

VL - 10

SP - 1711

EP - 1730

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 12

ER -